BioCentury
ARTICLE | Company News

Denovo gets rights to depression candidate, seeks biomarkers

April 24, 2017 9:55 PM UTC

Albany Molecular Research Inc. (NASDAQ:AMRI) granted Denovo Biopharma LLC (San Diego, Calif.) exclusive, worldwide rights to liafensine (DB104), a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI). Using its biomarker platform, Denovo hopes to analyze previous liafensine trial data and identify patient populations in which the candidate may treat depression effectively.

Denovo CBO Robert Little told BioCentury that the company will likely conduct a Phase IIb or Phase III study in both the U.S. and China, and possibly other countries. Both companies declined to disclose financial terms...